Abstract
Introduction
In 2006, the dyslipidemia market, valued at $27.7 billion in the US, Europe,
and Japan, reached its peak for the near future. Dominated by the statin drug
class, specifically Pfizer' s Lipitor, this highly lucrative market faced
significant generic erosion with the 2006 US patent expiration of Merck' s
Zocor and Bristol-Myers Squibb' s Pravachol. Of the seven drug classes in the
dyslipidemia market, five are highly genericized. Moreover, more than 20 drugs
are currently marketed for dyslipidemia, representing a crowded and
competitive landscape. However, unmet clinical need still exists and provides
an attractive commercial opportunity for new treatments that demonstrate
greater efficacy over existing treatment options.
From 2007 to 2011, two major events will occur in the dyslipidemia market:
Lipitor' s US and European patents will expire in 2010 and 2011, respectively;
and five new fixed dose combination (FDC) therapies will launch. In total,
seven emerging drugs are expected to launch before the end of 2011, including
the highly anticipated Cordaptive (extended-release niacin/laropiprant) from
Merck. Although a number of these emerging therapies are forecast for
blockbuster status, their revenues will not replace those lost to
genericization of the statins (specifically Lipitor) and the dyslipidemia
market will decline to a total market value of $22.0 billion in 2011.
Questions Answered in This Report
- Pfizer dominated the dyslipidemia market in 2006, with a market share in
excess of 45%; more than double that of the next leading competitor. With
generic simvastatin pressuring Lipitor, will Pfizer maintain its dominant
share? What strategies will the company employ to sustain their leading
position over the forecast period?
- Merck experienced a detrimental impact to their overall revenue with the
US patent expiration of Zocor in 2006. Nonetheless, by 2011 they will surpass
Pfizer as the leading company in revenue for dyslipidemia. How did Merck
sustain the blow of Zocor' s patent expiration and what strategies will the
company employ to surpass Pfizer?
- The dyslipidemia market is very lucrative, but competition for market
share is fierce. Thus, understanding current physician opinion continues to be
critical for companies to maintain or grow their share. We surveyed 64
cardiologists and primary care physicians on a range of topics influencing the
dyslipidemia market. Who do physicians think are the top companies and
brands in dyslipidemia? Which brand attributes are most important? What
channels do doctors use to find information about dyslipidemia and what
messaging in dyslipidemia do they find the most appealing?
- Statins dominate the dyslipidemia market; however, the drug class is
facing increasing generic erosion, which will peak in 2010 and 2011 when
Lipitor' s patent is set to expire in the US and Europe, respectively. The
genericization of the statin market will represent the biggest challenge to
companies seeking to retain significant earnings in this market, putting even
more pressure on companies to develop drug therapies that offer greater
efficacy than the current market leading statins. What products are major
competitors developing in their pipelines? How will the emerging drugs perform
if approved? Finally, which emerging drugs do physicians think will be the
most influential?
Scope
- Markets Covered: United States, France, Germany, Italy, Spain,
United Kingdom, and Japan.
Detailed discussion of major competitors including Pfizer, Merck,
Schering-Plough, Abbott, AstraZeneca, Novartis, and, Bristol-Myers Squibb as
well as the emerging competitors, Takeda and Isis Pharmaceuticals. Included is
an analysis of each company' s cardiovascular product portfolio, strategic
positioning, and development pipeline in dyslipidemia. The report features an
in-depth discussion of leading brands including approval history, sales and
market position, SWOT analysis, ongoing postmarketing clinical trials, and
strategic initiatives.
- Physician Perception of Key Brands: Analysis of physician
perceptions of the dyslipidemia market based on a custom survey of 64 US-based
primary care physicians and cardiologists. The survey is brand-focused and
examines physician perceptions of key competitors, brand attributes and
messaging, and uptake of emerging agents.
- Epidemiology: Total prevalent and diagnosed cases for each of the
major markets are presented in an annualized forecast from 2006 to 2011.
- Market Forecast: Annualized sales forecasts for branded agents,
including the uptake of new agents, presented by region, drug class, molecule,
and brand for 2006 to 2011.
View Cart
